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Abstract: Active smoking is associated with increased body burden of polycyclic aromatic
hydrocarbons (PAHs); the aim of this study was to assess whether environmental tobacco smoking
(ETS) increases the internal dose of PAHs. In 344 nonsmoking Italian adults, out of 497 individuals
selected as representative of the population of the town of Modena, ETS exposure was evaluated
by a self-administered questionnaire and by the measurement of urinary cotinine (COT-U).
PAH exposure was assessed by the measurement of urinary 1-hydroxypyrene (1-OHPYR) and
of ten urinary PAHs. In all subjects, median (5th–95th percentile) COT-U was 0.47 (<0.1–3.91) µg/L.
While 58 subjects reported to be ETS exposed (ETSQUEST), 38 individuals were identified as ETS
exposed on the basis of a COT-U value of 1.78 (90% confidence interval 1.75–1.80) µg/L, previously
derived as an upper reference value in not ETS exposed Italian adults (ETSCOT). Median COT-U levels
were 1.38 (<0.1–9.06) and 3.63 (1.80–17.39) µg/L in ETSQUEST and in ETSCOT subjects, respectively.
Significant correlations between COT-U and 1-OHPYR, and urinary anthracene, fluoranthene, pyrene,
and chrysene were found among all subjects. Significantly higher levels of 1-OHPYR, and urinary
fluorene, anthracene, and pyrene were found in ETSCOT individuals. The results of multiple linear
regression analyses, taking into consideration diet and other sources of PAHs exposures such as
the residence area/characteristics and traffic, confirmed that 1-OHPYR and urinary fluorene were
affected by ETS exposure, even if ETS played a minor role.
Keywords: environmental tobacco smoke; urinary cotinine; polycyclic aromatic hydrocarbons;
human biomonitoring; 1-hydroxypyrene
1. Introduction
Environmental tobacco smoke (ETS), also called passive smoke or involuntary smoking, is made
of several components: secondhand smoke, that is the combination of the mainstream smoke exhaled
by the smoker and of side-stream smoke released by the burning of the tobacco product, and thirdhand
smoke, that is residual tobacco smoke pollutants remaining on surfaces and dust after tobacco has
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been smoked and that react with oxidants and other compounds in the environment to form secondary
pollutants [1].
More than 4000 chemicals have been identified in ETS. Moreover, time and environmental
conditions make ETS composition and properties different from that of mainstream and side-stream
smoke. In particular, physicochemical properties of ETS vary in terms of both the proportion of
constituents in the particulate or in the vapor phase of smoke and the particle size. Moreover,
the concentrations of the individual constituents are different due to their dilution in the indoor
environment and to secondary reactions [2]. ETS, as well as active smoking, has been classified as
carcinogenic to humans, based on sufficient evidences of causing lung cancer, by the International
Agency for Research on Cancer (IARC) [2].
Among those chemicals contributing to ETS composition are Polycyclic Aromatic Hydrocarbons
(PAHs), which are a complex class of more than one hundred compounds formed by the incomplete
combustion of organic materials. PAHs, which have been identified in mainstream and in higher
amounts in side-stream smoke [3,4], have various chemical and toxicological properties. Some PAHs
have been classified as human carcinogens [5]; moreover, PAH exposure is associated with negative
reproductive, neurodevelopmental, cardiovascular, and inflammatory effects [6–9].
While the contribution of active tobacco smoke to PAH body burden is well known [10], few data
are available for ETS exposure [11,12]. Possible reasons may be found in the difficulty encountered in
defining ETS exposure as several variables, among which the ETS source, duration of exposure, distance
from the source, presence and effectiveness of a ventilation system, and personal characteristics, affect
the assessment of the inhaled dose. Moreover, as PAHs are ubiquitous pollutants of living and
occupational environments, possible sources of co-exposure should be taken into account in assessing
personal PAH exposure, such as the residence zone, traffic exposure, diet, cooking habits, and possible
occupational exposure.
PAH exposure can be assessed by human biomonitoring (HBM). PAHs, once absorbed in the body
are readily metabolized to phenols that are excreted in urine and feces as glucuronyl or glutathione
conjugates [13,14]. A small percentage of absorbed PAHs is excreted unmetabolized [15,16]. A very
interesting approach in the biological monitoring of PAH exposure is given by the obtainment
of a global profile of several urinary compounds that would be useful for obtaining a better
characterization of the exposure.
The aim of this study was to assess whether ETS increases the internal dose of PAHs in
a representative population of adults, using data that had been collected previously to study the
exposure to emissions from a local urban-waste incineration plant [17]. ETS exposure was evaluated
by both self-reporting and measurement of urinary cotinine (COT-U), a sensitive marker of both active
and passive smoke, for which we had previously derived an upper reference value of 1.78 µg/L,
in not ETS exposed Italian adults [18]. To evaluate PAH exposure, the measurement of urinary
1-hydroxypyrene (1-OHPYR), a routinely used biomarker of PAHs exposure, and of ten unmetabolized
PAHs (naphthalene, acenaphthylene, acenaphthene, fluorene, phenanthrene, anthracene, fluoranthene,
pyrene, benz[a]anthracene, and chrysene) was available. Moreover, the ETS role in determining the
total PAH burden, taking in account other potential PAH sources, was investigated using multiple
regression models.
2. Materials and Methods
2.1. Study Population and Sample Collection
The data presented in this paper have been collected through a cross-sectional biomonitoring study
on exposure to emissions from a local urban-waste incineration plant [19]. Recruitment, interviewing,
and sampling took place between November 2012 and April 2013. The study population consisted of
volunteer adult participants (18–70 years) from the general population of Modena, a medium-sized
town in Northern Italy (Emilia-Romagna region, Italy). Eligible subjects were randomly selected from
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the population base, which comprises approximately 40% of the town population. Sampling method
implied stratification by gender, age group (18–34, 35–49 and 50–69 years), and exposure. The study
sample was similar to the source population (the town population) in terms of sex, age, and citizenship
based on a comparison with data of the population register and of the health surveillance system.
The number of subjects to be included was calculated to detect a significant difference of at least
20% in biomarker levels comparing the most exposed to the least exposed subject; this results in about
500 individuals. Sampling comprised the selection of three replacements for each subject, belonging
to the same sampling stratum. Detailed information on the recruitment criteria and procedure was
described previously [17,18].
Invitations to participate in the study were sent out by post. Individuals were supplied with
a study pack containing the invitation letter, the questionnaire, a disposable polyethylene bottle, and the
instruction to collect a spot urine sample from the first void of the day. Subjects were telephonically
contacted about one week after the dispatch of the invitation letter and those answering positively were
invited to the Local Health Unit to provide the biological sample and to complete the questionnaire
on personal and lifestyle characteristics. Urine samples were immediately refrigerated at 4 ◦C and
delivered to the laboratory, where they were kept at −20 ◦C in the dark. Not-respondents and refusals
were substituted in an appropriate way to maintain the stratification homogeneity.
All participants were informed about the aims of the research and signed an informed consent
form. The study was approved by the ethics committee of Modena. The study has been carried out
in accordance with the Declaration of the World Medical Association (Declaration of Helsinki) for
experiments involving humans (http://www.wma.net/e/policy/b3.htm).
2.2. Questionnaire for Assessment of Active or Environmental Exposure to Tobacco Smoke
Participants completed a detailed questionnaire about current active and passive smoke
exposure [18]. The used items were adapted from available questionnaires used in large population
surveys and had been verified in our previous studies [18,20]. The questionnaire was reviewed by
a trained interviewer at the moment of urine sample collection. In particular, to classify current active
exposure to tobacco smoke, the following questions were asked: current active tobacco smoking
(yes/no), smoking product (cigarette/cigar/pipe/e-cigarette/other), product commercial name,
weekly and daily smoking intensities, and smoking environment (only open places/only closed
places/both open and closed places). To classify current ETS exposure, the following questions
were asked: living with smokers (yes/no), cohabitants smoked in the house (yes/no), working with
smokers (yes/no), coworkers smoked in the same room (yes/no), and daily ETS exposure within
the last week (yes/no). If a participant answered “yes” to the last question, then information on
ETS duration (how many days/week; how many hours/week; how many hours/day), smoking
type (cigarette/cigar/pipe smoke), and environment (home/work/leisure time/car; open/closed
places) was collected. Moreover, the time elapsed from the last smoke exposure to urine collection was
ascertained at the moment of urine collection.
2.3. Quantification of COT-U Level
Urinary cotinine (COT-U) was quantified by a liquid chromatography coupled to mass
spectrometry with triple quadrupole (LC-MS/MS) method [20]. The limit of quantification (LOQ) was
0.1 µg/L, range of linearity was 0.1–4000 µg/L, precision was <2%, and accuracy was ±1% of the
theoretical values. Subjects with COT-U >30 µg/L were classified as active smokers [18,20].
2.4. Urinary PAHs and 1-OHPYR Analysis
Prior to analysis, urinary samples were left at room temperature until completely thawed.
After shaking, two aliquots for the determination of urinary PAHs and 1-OHPYR were transferred to
the analysis vials and underwent the respective analytical procedures, as described below.
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Urinary PAHs [naphthalene (U-NAP), acenaphthylene (U-ACY), acenaphthene (U-ACE), fluorene
(U-FLU), phenanthrene (U-PHE), anthracene (U-ANT), fluoranthene (U-FLT), pyrene (U-PYR),
benz[a]anthracene (U-BaA), and chrysene (U-CHR)] were determined by solid-phase microextraction
(SPME) followed by gas chromatography coupled to mass spectrometry with triple quadrupole
(GC-MS/MS) [21]. Prior to analysis, samples were spiked with a mixture containing 10 deuterated
analogues as internal standards. Overall, LOQs were in the 0.2–5.4 ng/L range, within-run and
between-run precision, calculated on internal quality standards and expressed as the coefficient of
variation (CV%), were both <20%, and accuracy varied from 91 to 120%.
1-Hydroxypyrene (1-OHPYR) was determined by LC-MS/MS (TSQ Quantum Access, Thermo
Scientific, Rodano, Italy), after enzymatic hydrolysis and solid phase extraction. Analysis was
performed in the presence of a deuterated internal standard. LOQ was 0.05 µg/L, while precision and
accuracy, calculated on internal quality standards (0.5 and 2 µg/L), were <10% and in the 96–99% range,
respectively. Accuracy, calculated on low (NIST SRM 3673 Organic contaminants in non-smokers’
urine, 0.03 µg/L) and high (NIST SRM 3672 Organic contaminants in smokers’ urine, 0.17 µg/L)
standard reference materials was 79 and 107%, respectively.
2.5. Urinary Creatinine
Urinary creatinine was determined using Jaffe’s colorimetric method [22]. The creatinine value was
used to assure sample validity, excluding samples with excessive physiologic dilution or concentration
according to the 0.3 g/L ≤ creatinine ≤3.0 g/L range [23]. Moreover, creatinine was introduced in the
regression models as an independent variable [24].
2.6. Statistical Analysis
Statistical analysis was performed by using the IBM SPSS (ver. 24.0 for Windows; SPSS Statistics,
IBM Italia, Segrate, Italy) and by the STATA 11 software packages (Stata Corp LP, College Station,
TX, USA). The median and percentiles of COT-U and PAH biomarkers were used to describe the
non-parametric distributions in all subjects and in subgroups stratified by ETS exposure. Active
smoking was defined as self-reported current smoking or COT-U levels ≥ 30 µg/L. Among correctly
identified nonsmokers (individuals self-classified as nonsmokers and with COT-U < 30 µg/L), subjects
were classified as ETS exposed alternatively based on the questionnaire, when daily ETS exposure
within the last week was reported in the questionnaire (ETSQUEST), or based on a COT-U value of
1.78 (90% confidence interval 1.75–1.80) µg/L, previously derived as upper reference value in not ETS
exposed Italian adults (ETSCOT) [18].
Pearson’s correlations were used to test the associations between variables. The Student’s t test
for independent samples was used on decimal log-transformed data for the univariate evaluation of
differences between groups. The chi-square test was used to compare the percentage distributions
among groups.
For each biomarker, three multivariate linear regression models were estimated to study the
influence of ETS exposure on PAH body burden. ETS exposure was introduced in the regression models
alternatively as a continuous variable (not transformed COT-U, µg/L, Model 1) or as a dichotomous
variable (ETSCOT in Model 2 or ETSQUEST in Model 3). Considering the large number of confounding
factors that may influence PAH exposure, an extensive pool of complementary information including
diet, environmental sources of exposure, occupational exposure, characteristic of the residence,
atmospheric parameters, and personal habits, was collected by a detailed questionnaire, as described
previously [17]. Covariates included in the finals models were those found to have a significant effect
in preliminary regression analysis or known to affect biomarkers based on the pertinent literature.
Some covariates were included in models as fixed variables, regardless of the statistical significance:
gender, age, education level (low/high), citizenship (Italian/others), body mass index, creatinine,
residence zone (rural, industrial, urban, mixed), daily temperature, precipitation, outdoor traffic
exposure (low, medium, high), heating exposure (NOx), time spent at home (h/day), residential
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distance from major roads, and occupational exposure to PAHs (yes/no). The sampling day was
introduced as a spline variable (with up to three knots) to control for exposure variability.
To account for the impact of a potential selection bias, the Inverse Probability Weighting
(IPW) was calculated; the weighting allows to correct for the likelihood of adherence estimated
by socio-demographic variables (gender, age, citizenship), which were the only markers available in
the administrative database both for respondents and non-respondents. Unfortunately, the education
level, which is known to be related to compliance, as well as the other used socio-demographic
variables, was not available in the administrative database.
In the regression models, PAH biomarkers were transformed according to the distribution
characteristics by Box-Cox transformation. A logarithmic transformation was applied if the lambda of
the Box-Cox transformation was equal to zero. For biomarker values below the LOQ the actual values
were used. Outliers, defined as samples with biomarker levels above the 99th percentile, were excluded
from statistical analysis. Samples with creatinine concentrations above 3 g/L or below 0.3 g/L were
excluded as well.
3. Results
3.1. Study Population
Figure 1 shows the participant flow-chart. Among 497 individuals recruited to the biomonitoring
study (response rate 53.5%, non-availability rate 19.2%, refusal rate: 27.3%), two participants were
excluded from the analysis because they did not complete the questionnaire, while 151 were identified
as active smokers and were excluded as well. Finally, 344 individuals were identified as nonsmokers
and were included in this study. Their mean age (minimum-maximum) was 45 (18–69) years,
183 (53%) participants were female, 324 (94%) were white individuals from Italy or other European
countries (Table 1).
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Table 1. Characteristics of participants (n = 344), stratified by environmental tobacco smoke (ETS) exposure based on COT-U excretion (ETSCOT: COT-U > 1.78 µg/L =
ETS exposed) and on self-classification by questionnaire (ETSQUEST).
Characteristics
All Subjects N (%)
ETS Exposure by Questionnaire N (%) ETS Exposure by COT-U N (%)
No-ETS Exposure ETS Exposure (ETSQUEST) p * No-ETS Exposure ETS Exposure (ETSCOT) p *
344 286 (83) 58 (17) - 306 (89) 38 (11) -
Age (years) Mean (minimum-maximum) 45 (18–69) 46 (18–69) 40 (18–68) 0.004 45 (18–69) 42 (18–68) 0.122
Age (class) N (%)
18–34 96 (28) 70 (2) 26 (45)
0.004 χ
81 (26) 15 (39)
0.240 χ35–49 111 (32) 99 (35) 12 (21) 101 (33) 10 (26)
50–69 137 (40) 117 (41) 20 (34) 124 (41) 13 (34)
Gender N (%) Male 161 (47) 138 (48) 23 (40) 0.191 χ
163 (53) 20 (53)
0.941 χFemale 183 (53) 148 (52) 35 (60) 143 (47) 18 (47)
Education N (%)
Primary school 13 (9) 9 (3) 4 (7)
0.077 χ
10 (3) 3 (8)
0.361 χ
Secondary school 82 (24) 63 (22) 19 (33) 71 (23) 11 (29)
High school 144 (42) 122 (43) 22 (38) 131 (43) 13 (34)
Graduated 103 (30) 90 (31) 13 (22) 93 (30) 10 (26)
Income (€/month)
N (%)
No income 3 (1) 3 (1) 0 (0)
0.452 χ
3 (1) 0
0.700 χ
<1000 24 (7) 20 (7) 4 (7) 22 (7) 2 (5)
1001–2000 94 (27) 75 (26) 19 (33) 80 (26) 14 (37)
2001–3000 99 (29) 78 (27) 21 (36) 91 (30) 8 (21)
3001–5000 76 (22) 68 (24) 8 (14) 68 (22) 8 (21)
>5000 23 (7) 21 (7) 2 (3) 21 (7) 2 (5)
Don’t know/missing 25 (7) 18 (6) 4 (7) 21 (7) 4 (10
Ethnicity
European whites 324 (94) 271 (95) 53 (91)
0.311 χ
289 (94) 35 (92)
0.416 χ
Non-European whites 8 (2) 7 (2) 1 (2) 7 (2) 1 (3)
African blacks 5 (1) 4 (1) 1 (2) 5 (2) 0 (0)
Others 7 (2) 4 1) 3 (5) 5 (2) 2 (5)
ETS duration (h/day) Mean
(minimum-maximum) - - 2 (0–10) - 1 (0–4) 3 (0–10) 0.054
ETS duration (h/week) Mean
(minimum-maximum) - - 10 (0–70) - 6 (0–28) 18 (0–70) 0.035
ETS duration (day/week) Mean
(minimum-maximum) - - 5 (1–7) - 4 (1–7) 6 (2–7) 0.002
COT-U (µg/L) Median (5th–95th percentile) 0.47 (<0.1–3.91) 0.39 (<0.1–1.78) 1.38 (<0.1–9.06) <0.001 0.40 (<0.1–1.32) 3.63 (1.8–17.39) <0.001
* = Determined by Student’s t or chi-square test comparing ETS-exposed vs. non-ETS exposed subjects; χ = Determined by chi-square test.
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3.2. ETS Exposure
In all subjects, the median (5th–95th percentile) COT-U was 0.47 (<0.1–3.91) µg/L. According
to the questionnaire, 58 (17%) subjects reported daily ETS exposure within the last week (ETSQUEST),
whereas 286 (83%) reported no daily ETS exposure (Figure 1). Their median COT-U levels were
1.38 (<0.1–9.06) and 0.39 (<0.1–1.78) µg/L, respectively (p < 0.001). Subjects reporting ETS exposure
were younger than those not reporting exposure (40 vs. 46 years, p = 0.004), were predominantly
female (60% female vs. 40% male), and had a lower education level (Table 1). ETSQUEST subjects
reported mean ETS exposure for 2 h/day, 10 h/week, and 5 day/week.
Based on the COT-U value of 1.78 µg/L, 38 (11%) individuals were identified as ETS exposed
(ETSCOT) and 306 (89%) as not-ETS exposed (Figure 1). Their median COT-U levels were 3.63 (1.8–17.39)
and 0.40 (<0.1–1.32) µg/L, respectively (p < 0.001). No difference in terms of age, gender, and education
was found between ETSCOT and not-ETS exposed subjects (Table 1). In ETSCOT subjects, ETS duration
was significantly longer than in not-ETS exposed subjects (3 vs. 1 h/day, 18 vs. 6 h/week, and 6 vs.
4 day/week, respectively).
Twenty-three subjects reported to be ETS exposed and had COT-U levels higher than 1.78 µg/L.
3.3. PAH Exposure and ETS
Table 2 reports the results of urinary PAH and 1-OHPYR levels in all subjects and in subjects
stratified by ETS exposure based on self-classification by questionnaire and on COT-U excretion.
Considering all subjects together, urinary PAHs were detected at least in 65% of samples, beside
U-BaA, that was detected only in 18% of samples. U-NAP, U-PHE, and U-ANT were detected in all
samples. 1-OHPYR was quantified only in 33% of subjects.
In subjects stratified by ETS exposure based on self-reporting, the percentage of analytes above
the LOQ was similar between ETSQUEST and not-exposed individuals. Urinary PAH or 1-OHPYR
levels were not different comparing ETSQUEST vs. not-exposed individuals; only for U-ANT, slightly
higher levels were observed in ETSQUEST than in not-exposed subjects (2.0 vs. 2.2 µg/L, p = 0.102).
In subjects stratified by ETS exposure based on COT-U excretion, the percentage of analytes above
the LOQ was similar between ETSCOT and not-exposed individuals; only for U-ACE and 1-OHPYR
a slightly higher percentage of samples above the LOQ was found in ETSCOT than in not-exposed
subjects (89 vs. 78%, p = 0.102; and 42 vs. 32% p = 0.213, respectively). Significantly higher levels of
1-OHPYR (p = 0.037), U-FLU (p = 0.028), U-ANT (p = 0.028), and U-PYR (p = 0.052) were found in
ETSCOT than in not-exposed individuals.
Int. J. Environ. Res. Public Health 2018, 15, 1156 8 of 15
Table 2. Urinary 1-OHPYR and PAH levels in subjects stratified by ETS exposure based on COT-U excretion (ETSCOT: COT-U > 1.78 µg/L) and on self-classification
by questionnaire (ETSQUEST).
Analyte All Subjects (N = 344)
ETS Exposure by Questionnaire ETS Exposure by COT-U
No-ETS Exposure
(N = 286)
ETS Exposure (ETSQUEST)
(N = 58)
p *
No-ETS Exposure
(N = 306)
ETS Exposure (ETSCOT)
(N = 38)
p *
Median (5–95 percentile);
% > LOQ
Median (5–95 percentile);
% > LOQ
Median (5–95 percentile);
% > LOQ
Median (5–95 percentile);
% > LOQ
Median (5–95 percentile);
% > LOQ
1-OHPYR µg/L <0.05 (<0.05–0.13); 33 <0.05 (<0.05–0.13); 34 <0.05 (<0.05–0.11); 31 0.395 <0.05 (<0.05–0.12); 32 <0.05 (<0.05–0.17); 42 0.037
U-NAP ng/L 24.7 (13.4–78.7); 100 24.6 (13.0–80.0); 100 25.1 (14.2–65.3); 100 0.742 24.7 (13.4–80.0); 100 25.1 (12.5–63.3); 100 0.516
U-ACY ng/L 0.5 (<0.3–1.5); 95 0.5 (<0.3–1.5); 95 0.6 (<0.3–1.7); 95 0.517 0.5 (0.3–1.5); 95 0.6 (<0.3–1.5); 92 0.937
U-ACE ng/L 0.9 (<0.6–3.4); 79 0.9 (<0.6–3.4); 78 1.0 (<0.6–3.0); 85 0.889 0.9 (<0.6–3.5); 78 0.9 (<0.6–2.1); 89 0.768
U-FLU ng/L 1.5 (0.9–2.9); 96 1.5 (0.9–2.8); 96 1.5 (1.0–2.9); 97 0.798 1.5 (0.9–2.8); 96 1.7 (1.0–3.2); 100 0.028
U-PHE ng/L 7.2 (4.7–14.6); 100 7.2 (4.6–14.1); 100 7.1 (5.0–17.2); 100 0.566 7.1 (4.7–14.9); 100 7.7 (5.0–13.5); 100 0.274
U-ANT ng/L 2.1 (0.9–3.1); 100 2.0 (0.9–3.1); 100 2.2 (0.8–5.7); 100 0.102 2.1 (0.9–3.1); 100 2.3 (1.0–3.3); 100 0.028
U-FLT ng/L 0.7 (<0.6–1.3); 72 0.7 (<0.6–1.3); 72 0.6 (<0.6–1.4); 69 0.728 0.7 (<0.6–1.2); 71 0.8 (<0.6–1.5); 73 0.340
U-PYR ng/L 0.6 (<0.4–1.1); 92 0.6 (<0.4–1.1); 91 0.6 (<0.4–1.3); 95 0.323 0.6 (<0.4–1.1); 92 0.7 (<0.4–1.3); 89 0.052
U-BaA ng/L <0.3 (<0.3–0.8); 18 <0.3 (<0.3–0.8); 19 <0.3 (<0.3–1.4); 17 0.809 <0.3 (<0.3–0.8); 19 <0.3 (<0.3–2.1); 13 0.716
U-CHR ng/L 0.2 (<0.2–0.7); 65 0.2 (<0.2–0.6); 64 0.2 (<0.2–1.7); 67 0.223 0.2 (<0.2–0.7); 65 0.2 (<0.2–1.4); 66 0.398
* = Determined by Student’s t test comparing ETS-exposed vs. non-ETS exposed subjects.
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3.4. Contribution of ETS to PAH Exposure
In all subjects, COT-U levels were significantly, or marginally significantly, correlated with
1-OHPYR (Pearson’s r = 0.121, p = 0.024), U-ANT (r = 0.128, p = 0.017), U-FLT (r = 0.094, p = 0.083),
U-PYR (r = 0.106, p = 0.051), and U-CHR (r = 0.114, p = 0.035).
Table 3 shows the results of the adjusted linear regression models in detail. Only beta-coefficients
(β) of ETS exposure, together with the 95% confidence intervals, are shown regardless of the significance
level. Due to the outlier exclusion, the sample size was different for each PAH biomarker and ranged
from 287 (1-OHPYR) to 313 (U-ACY, U-FLU, and U-FLT). The complete regression model, showing
beta-coefficients for all the independent variables, is shown in Supplementary Table S1 for Model 1.
Multivariate regression models were performed for each analyte, except for U-BaA, given the high
proportion of samples with levels below the LOQ for this biomarker.
When ETS exposure was introduced in the regression model as a continuous variable (unadjusted
COT-U levels, Model 1), ETS was associated to 1-OHPYR (beta 0.042, p = 0.026), with a 4% percentage
increment for each 10-fold increase in cotinine excretion. The other variables associated to 1-OHPYR were
creatinine (beta = 0.680, p < 0.001), coffee intake (beta= 0.267, p = 0.074), education level (beta = 0.243,
p = 0.069), and the sampling day (beta = 0.007, p < 0.001). A marginal association between ETS and
U-ANT was also suggested by the model (beta 0.015, p = 0.134). Other variables positively affecting
PAH biomarkers in this model were the sampling day (1-OHPYR, U-ACY, U-ANT, and U-CHR),
the exposure to the waste incineration emissions (U-FLU), gender (U-PHE and U-CHR), the education
level (1-OHPYR), the citizenship (U-NAP, U-FLU, U-PHE, U-FLT, U-PYR, and U-CHR), creatinine
(1-OHPYR, U-PHE, and U-ANT), living in an industrial or urban area (U-NAP), daily precipitation
(U-ACY), medium or high traffic exposure (U-ACY, U-FLU, and U-ANT), heating emission exposure
(U-ACY and U-FLU), the presence of mold on the residence wall (U-NAP, U-ACY, U-FLU, U-PHE,
U-ANT, U-FLT), the use of chemicals in domestic environments (U-ANT), the use of medication
(U-ACE), or nutritional supplement ((U-FLT), and some specific food such as tuna (U-ACE), coffee
(1-OHPYR), and wine (U-NAP) (Supplementary Table S1).
When ETS exposure was introduced in the regression model as a dichotomous variable based on
COT-U excretion (ETSCOT, Model 2), only U-FLU resulted influenced by ETS (beta = 0.126, p = 0.061).
The other variables associated to U-FLU were the citizenship (beta = 0.126, p = 0.067, the sampling day
(beta = 0.096, p < 0.001), the exposure to the waste incineration emissions (level 2, beta = 0.147, p = 0.027,
and level 3 = 0.166, p = 0.008), age (beta = 0.003, p = 0.092), creatinine (beta = −0.064, p = 0.071), living
in a rural area (urban area, beta = −0.230, p = 0.004, and mixed area, beta = −0.138, p = 0.065), medium
traffic exposure (beta = 0.126, p = 0.006), heating emission exposure (beta = 0.009, p = 0.002), and the
presence of mold on the residence wall (beta = 0.117, p = 0.028).
When ETS exposure was introduced in the regression model as a dichotomous variable based
on self-classification by questionnaire (ETSQUEST, Model 3), none of the PAH biomarker resulted
associated to ETS.
For both Model 2 and Model 3, the results regarding other variables affecting PAH biomarkers
were very similar to what is shown for Model 1 in Supplementary Table S1.
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Table 3. Results of multiple linear regression analyses for predicting the levels of urinary PAHs and
1-OHPYR in study subjects. ETS exposure was introduced in the regression models alternatively as
a continuous variable (unadjusted COT-U levels, Model 1), or as a dichotomous variable (ETSCOT
in Model 2, and ETSQUEST in Model 3). Beta-coefficients (β) of ETS exposure, together with the
95% confidence intervals, are shown regardless of the significance level. The complete regression model
is shown in Supplementary Table S1 for Model 1.
Analyte Statistics a,b
Model 1 Model 2 Model 3
COT-U (µg/L) ETSCOT ETSQUEST
1-OHPYR *
Beta (std) 0.043 (0.019) 0.078 (0.194) −0.017 (0.144)
95%CI 0.005–0.080 −0.304–0.461 −0.300–0.266
p 0.026 0.687 0.906
U-NAP
Beta (std) 0.002 (0.003) 0.014 (0.025) 0.005 (0.024)
95%CI −0.004–0.009 −0.035–0.064 −0.043–0.053
p 0.476 0.572 0.842
U-ACY
Beta (std) −0.003 (0.012) 0.076 (0.100) −0.049 (0.087)
95%CI −0.027–0.020 −0.119–0.271 −0.221–0.123
p 0.781 0.445 0.573
U-ACE *
Beta (std) −0.003 (0.013) 0.003 (0.103) 0.060 (0.106)
95%CI −0.028–0.023 −0.200–0.205 −0.149–0.270
p 0.821 0.979 0.572
U-FLU
Beta (std) 0.003 (0.011) 0.126 (0.067) 0.035 (0.054)
95%CI −0.017–0.024 −0.006–0.258 −0.071–0.140
p 0.743 0.061 0.520
U-PHE
Beta (std) −0.000 (0.001) 0.000 (0.010) −0.008 (0.011)
95%CI −0.003–0.002 −0.0189–0.019 −0.030–0.015
p 0.737 0.980 0.503
U-ANT
Beta (std) 0.015 (0.010) 0.024 (0.087) 0–0.018 (0.073)
95%CI −0.005–0.034 −0.147–0.194 −0.162–0.126
p 0.134 0.784 0.804
U-FLT
Beta (std) 0.009 (0.008) 0.0480 (0.067) −0.032 (0.053)
95%CI −0.008–0.0247 −0.084–0.179 −0.135–0.071
p 0.299 0.474 0.545
U-PYR
Beta (std) 0.004 (0.007) 0.040 (0.063) 0.000 (0.049)
95%CI −0.010–0.017 −0.085–0.163 −0.097–0.097
p 0.616 0.534 0.999
U-CHR *
Beta (std) −0.015 (0.013) −0.007 (0.100) −0.056 (0.092)
95%CI −0.041–0.011 −0.204–0.190 −0.238–0.126
p 0.254 0.944 0.547
a = In model 2 and 3, not-exposed subjects were the reference group. b = p values represent significance of ETS
exposure for each PAH biomarker. * = logarithmic transformation.
4. Discussion
4.1. Biomarkers of ETS and PAH Exposure
In this study, urinary cotinine was measured in samples from 344 individuals from a representative
group of the general population. Among the investigated subjects, 58 (17%) reported being daily ETS
exposed (ETSQUEST) (Table 1). Median COT-U levels in these subjects were higher than those in subjects
not reporting ETS exposure (1.38 vs. 0.39 µg/L, p < 0.001) and consistent with those found in studies
conducted in countries where a smoking-ban in public places has been implemented [25,26]. As several
variables may affect ETS exposure (i.e., source, duration, intensity) and certain individuals may be
particularly prone to report it, the use of the upper reference value of CUT-U (1.78 µg/L) as a cut-off
value allowed us to identify those individuals who were exposed to high ETS level (ETSCOT). Median
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COT-U levels (3.63 µg/L) in these subjects were similar to those previously reported in non-smoking
adults before the smoking-ban was implemented [12,27–29].
The exposure to PAHs was evaluated by measuring urinary 1-OHPYR and ten unmetabolized
PAHs (Table 2). In all subjects, 1-OHPYR was quantifiable only in 33% of the samples, with median
levels <0.05 µg/L and well below the reference value for the Italian population (<0.3 µg/L in
non-smokers and <0.7 µg/L in smokers) [30]. Urinary PAHs, except U-BaA, were quantifiable in the
large majority of samples, even though median levels of all analytes were very low (ng/L order of
magnitude). Not so many studies reported the measurement of urinary PAHs in the general population:
the levels here found were similar or lower than those reported for adults in the town of Modena [31]
and in a small group of adolescents participating in the Flemish Environment and Health Study [32],
and much lower than those of non-smoking adults living in an industrial polluted area in Poland [33].
Altogether, PAH biomarkers measured in this study are indicative of very low PAH exposure.
4.2. ETS and PAH Exposure
The possible role of ETS in determining PAH intake has been seldom investigated. Higher levels
of PAH metabolites in ETS exposed adults than in not-exposed were reported for 1-OHPYR with
a linear relationship between 1-OHPYR excretion and duration of ETS exposure [34], for hydroxylated
metabolites of phenanthrene and again 1-OHPYR in highly ETS exposed subjects [12], and for
hydroxylated metabolites of phenanthrene, fluorene, and pyrene in the U.S. general population
participating in the 1999–2002 National Health and Nutrition Examination Survey [11]. More recently,
1-OHPYR was found higher in adults exposed to ETS during the weekend or more than 4 h/day along
the week than in not-exposed adults participating in a human biomonitoring program on a national
scale in Spain [35]. Among several PAH biomarkers investigated in this study, the levels of 1-OHPYR,
U-FLU, U-ANT, and U-PYR were significantly higher in subjects stratified as ETS-exposed based on
COT-U excretion (ETSCOT subjects) (Table 2). Thus, consistently with previous reports, higher exposure
to PAHs was evident only in highly ETS-exposed subjects.
As regards the exposure to specific PAHs, a very interesting result of this study is that U-FLU
was higher in ETSCOT subjects than in not-ETS exposed subjects (Table 2). Fluorene, which is
a low-molecular weight PAH with three aromatic rings like anthracene, resulted among the compounds
more contributing to mainstream smoke composition (as ng/cigarette) and among the most abundant
in the gas phase of tobacco smoke [4]. Previous studies indicated fluorene hydroxylated metabolites
as more specific and selective biomarkers than 1-OHPYR to discriminate PAH exposure in smokers
and nonsmokers [10,36]. Our present results suggest that U-FLU may be indicative of exposure to
low-molecular weight compounds in ETS-exposed subjects too.
Positive correlations were found between COT-U and some of the measured PAH biomarkers,
including 1-OHPYR, U-ANT, U-FLT, U-PYR, and U-CHR. It is interesting that 4-ring PAHs, such as
fluoranthene, pyrene and chrysene, are among the most important contributors to side-stream
smoke [3]. This result is consistent with a previous study where a correlation between environmental
chrysene exposure and urinary cotinine was shown [12] and it highlights the existence of a relation
between ETS exposure and particle-bound PAHs.
4.3. Role of ETS in Determining PAH Exposure
Given that PAHs are originated from multiple sources and co-exposure is very common, especially
in not-occupationally exposed individuals, the regression analysis enabled us to evaluate the role of
ETS exposure in determining PAH exposure (Table 3 and Supplementary Table S1). The regression
models suggested a weak contribution of ETS to PAH intake and only when ETS was defined by
COT-U excretion (both as continuous variable in Model 1, and as a dichotomous variable in Model 2).
This underlines that the questionnaire may be not an adequate tool to define ETS exposure for the
wide variability of ETS exposure occurrence and the consequent individual’s difficulty in recognizing
and/or recalling it [18].
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Among the measured biomarkers, significant or marginally significant associations with COT-U
were found only for 1-OHPYR (with a percentage increment of 4% for each 10-fold increase in cotinine
excretion) and for U-FLU, partly confirming the results of the univariate analysis.
Moreover, the regression analysis highlighted that ETS is a minor source of PAH exposure among
other sources: other contributors to 1-OHPYR excretion were creatinine, the education level, and the
intake of coffee, while other contributors to U-FLU excretion were the exposure to the waste incinerator
emissions, the residence area, the exposure to traffic, and the presence of mold on the residence wall
(Supplementary Table S1). While some associations may be expected, such as those found with diet,
traffic exposure, and the residence area, others, among which the presence of mold on the residence
wall, the education level, and the citizenship may be not so obvious and may be proxies of other factors
(i.e., different diet, cooking habits, lifestyle, and residence characteristics).
4.4. Limitations and Strengths
Some limitations may be identified in this study, such as the lack of PAH personal air
measurements that would have allowed making associations between PAH exposure from ETS and
biomarkers. Moreover, even if the original sample population consisted of about 500 individuals,
with a sample size adequate to observe a significant difference in the biomarkers levels, the number of
ETS exposed subjects was actually small, which may have influenced the robustness of the present
findings. The strength of this study is that several PAH biomarkers were investigated simultaneously
on a representative group of the general population, giving the opportunity to better characterize the
exposure profile. Few studies reported the association between ETS and PAH exposure, and only
hydroxylated metabolites were investigated [11,12], whereas this is the first time that unmetabolized
PAHs have been studied to this aim. Moreover, other potential sources of possible PAH exposure were
carefully accounted for by regression models allowing us to investigate the role of ETS in determining
PAH body burden.
5. Conclusions
In conclusion, this study highlighted a weak, but significant, contribution of ETS exposure to the
PAH body burden, as shown by 1-OHPYR and fluorene increases in ETS exposed individuals. On the
other hand, our results suggest that ETS exposure experienced by subjects in this study represents
a minor source of exposure to PAHs.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/15/6/1156/
s1, Table S1: Estimates of regression models using urinary PAHs as dependent variables. Beta-coefficients (β) of
COT-U are shown regardless of the significance level, whereas only β values below the 0.10 significance level are
illustrated for the other covariates.
Author Contributions: P.B., G.G., A.R., P.L., G.C., and S.F. conceived and designed the experiments; L.C., E.P.,
and L.O. performed the experiments; L.C., G.Q., and M.R. analyzed the data; L.C. and S.F. wrote the paper.
Acknowledgments: The study was funded by the Province of Modena in the frame of the authorization for an
upgrade of the local SWI (resolution n◦ 74 of 02/02/2007).
Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish the results.
References
1. Matt, G.E.; Quintana, P.J.E.; Destaillats, H.; Gundel, L.A.; Sleiman, M.; Singer, B.C.; Jacob, I.P.; Benowitz, N.L.;
Winickoff, J.P.; Rehan, V.; et al. Thirdhand tobacco smoke: Emerging evidence and arguments for
a multidisciplinary research agenda. Environ. Health Perspect. 2011, 119, 1218–1226. [CrossRef] [PubMed]
2. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks
to Humans. Tobacco Smoke and Involuntary Smoking; World Health Organization: Lyon, France, 2004; Volume 83.
Int. J. Environ. Res. Public Health 2018, 15, 1156 13 of 15
3. Lodovici, M.; Akpan, V.; Evangelisti, C.; Dolara, P. Sidestream tobacco smoke as the main predictor of
exposure to polycyclic aromatic hydrocarbons. J. Appl. Toxicol. 2004, 24, 277–281. [CrossRef] [PubMed]
4. Ding, Y.S.; Trommel, J.S.; Yan, X.J.; Ashley, D.; Watson, C.H. Determination of 14 PAHs in mainstream smoke
from domestic cigarettes. Environ. Sci. Technol. 2005, 39, 471–478. [CrossRef] [PubMed]
5. International Agency for Research on Cancer (IARC). Some Non-Heterocyclic Polycyclic Aromatic Hydrocarbons
and Some Related Exposures. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; International
Agency for Reaserch on Cancer (IARC): Lyon, France, 2010; Volume 92.
6. Choi, H.; Perera, F.; Pac, A.; Wang, L.; Flak, E.; Mroz, E.; Jacek, R.; Chai-Onn, T.; Jedrychowski, W.; Masters, E.;
et al. Estimating individual-level exposure to airborne polycyclic aromatic hydrocarbons throughout the
gestational period based on personal, indoor, and outdoor monitoring. Environ. Health Perspect. 2008, 116,
1509–1518. [CrossRef] [PubMed]
7. Edwards, S.C.; Jedrychowski, W.; Butscher, M.; Camann, D.; Kieltyka, A.; Mroz, E.; Flak, E.; Li, Z.; Wang, S.;
Rauh, V.; et al. Prenatal exposure to airborne polycyclic aromatic hydrocarbons and Children’s intelligence
at 5 years of age in a prospective cohort study in Poland. Environ. Health Perspect. 2010, 118, 1326–1331.
[CrossRef] [PubMed]
8. Xu, X.; Cook, R.L.; Ilacqua, V.A.; Kan, H.; Talbott, E.O.; Kearney, G. Studying association between urinary
metabolites of polycyclic aromatic hydrocarbons (PAHs) and cardiovascular diseases in the United States.
Sci. Total Environ. 2010, 408, 4943–4948. [CrossRef] [PubMed]
9. Zhou, Y.; Liu, Y.; Sun, H.; Ma, J.; Xiao, L.; Cao, L.; Li, W.; Wang, B.; Yuan, J.; Chen, W. Associations of
urinary polycyclic aromatic hydrocarbon metabolites with fractional exhaled nitric oxide and exhaled carbon
monoxide: A cross-sectional study. Sci. Total Environ. 2018, 618, 542–550. [CrossRef] [PubMed]
10. St Helen, G.; Goniewicz, M.L.; Dempsey, D.; Wilson, M.; Jacob, P.; Benowitz, N.L. Exposure and kinetics
of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem. Res. Toxicol. 2012, 25, 952–964.
[CrossRef] [PubMed]
11. Suwan-ampai, P.; Navas-Acien, A.; Strickland, P.; Agnew, J. Involuntary tobacco smoke exposure and urinary
levels of polycyclic aromatic hydrocarbons in the United States, 1999 to 2002. Cancer Epidemiol. Biomark. Prev.
2009, 18, 884–893. [CrossRef] [PubMed]
12. Aquilina, N.J.; Delgado-Saborit, J.M.; Meddings, C.; Baker, S.; Harrison, R.M.; Jacob, P., III; Wilson, M.; Yu, L.;
Duan, M.; Benowitz, N.L. Environmental and biological monitoring of exposure to PAHs and ETS in the
general population. Environ. Int. 2010, 36, 763–771. [CrossRef] [PubMed]
13. Grover, P.L. Pathways involved in the metabolism and activation of polycyclic hydrocarbons. Xenobiotica
1986, 16, 915–931. [CrossRef] [PubMed]
14. Ramesh, A.; Walker, S.A.; Hood, D.B.; Guillén, M.D.; Schneider, K.; Weyand, E.H. Bioavaibility and risk
assement of orally ingested polycyclic aromatic hydrocarbons. Int. J. Toxicol. 2004, 23, 301–333. [CrossRef]
[PubMed]
15. Waidyanatha, S.; Zheng, Y.; Rappaport, S.M. Determination of polycyclic aromatic hydrocarbons in urine of
coke oven workers by headspace solid phase microextraction and gas chromatography-mass spectrometry.
Chem. Biol. Interact. 2003, 145, 165–174. [CrossRef]
16. Campo, L.; Fustinoni, S.; Buratti, M.; Cirla, P.; Martinotti, I.; Foà, V. Unmetabolized polycyclic aromatic
hydrocarbons in urine as biomarkers of low exposures in asphalt workers. J. Occup. Environ. Hyg. 2007, 4,
100–110. [CrossRef]
17. Gatti, M.G.; Bechtold, P.; Campo, L.; Barbieri, G.; Quattrini, G.; Ranzi, A.; Sucato, S.; Olgiati, L.; Polledri, E.;
Romolo, M.; et al. Human biomonitoring of polycyclic aromatic hydrocarbons and metals in the general
population residing near the municipal solid waste incinerator of Modena, Italy. Chemosphere 2017, 186,
546–557. [CrossRef] [PubMed]
18. Campo, L.; Polledri, E.; Bechtold, P.; Gatti, G.; Ranzi, A.; Lauriola, P.; Goldoni, C.A.; Bertazzi, P.A.; Fustinoni, S.
Determinants of active and environmental exposure to tobacco smoke and upper reference value of urinary
cotinine in not exposed individuals. Environ. Res. 2016, 148, 154–163. [CrossRef] [PubMed]
19. AIA Study. Progetto A.I.A—Sorveglianza e biomonitoraggio di una coorte di modenesi residenti nell’area
circostante l’impianto di incenerimento urbano. [Health Surveillance and Biomonitoring of a Cohort of
Subjects Living in the Vicinity of an Urban Solid-Waste Incinerator]. Available online: http://www.Ausl.Mo.
It/dsp/flex/cm/pages/serveblob.Php/l/it/idpagina/3472 (accessed on 29 June 2015).
Int. J. Environ. Res. Public Health 2018, 15, 1156 14 of 15
20. Fustinoni, S.; Campo, L.; Polledri, E.; Mercadante, R.; Erspamer, L.; Ranzi, A.; Lauriola, P.; Goldoni, C.A.;
Bertazzi, P. A validated method for urinary cotinine quantification used to classify active and environmental
tobacco smoke exposure. Curr. Anal. Chem. 2013, 9, 447–456. [CrossRef]
21. Campo, L.; Fustinoni, S.; Bertazzi, P. Quantification of carcinogenic 4- to 6-ring polycyclic aromatic
hydrocarbons in human urine by solid-phase microextraction gas chromatography-isotope dilution mass
spectrometry. Anal. Bioanal. Chem. 2011, 401, 625–634. [CrossRef] [PubMed]
22. Kroll, M.H.; Chesler, R.; Hagengruber, C.; Blank, D.W.; Kestner, J.; Rawe, M. Automated determination of
urinary creatinine without sample dilution: Theory and practice. Clin. Chem. 1986, 32, 446–452. [PubMed]
23. World Health Organization (WHO). Biological Monitoring of Chemical Exposure in the Workplace; WHO:
Geneva, Switzerland, 1996; Volume 1.
24. Barr, D.B.; Wilder, L.C.; Caudill, S.P.; Gonzalez, A.J.; Needham, L.L.; Pirkle, J.L. Urinary creatinine
concentrations in the U.S. population: Implications for urinary biologic monitoring measurements.
Environ. Health Perspect. 2005, 113, 192–200. [CrossRef] [PubMed]
25. BalbèŠ, M.; Martinez-Sanchez, J.M.; Sureda, X.; Fu, M.; Pérez-Ortuño, R.; Pascual, J.A.; Saltó, E.; Fernández, E.
Cigarettes vs. E-cigarettes: Passive exposure at home measured by means of airborne marker and biomarkers.
Environ. Res. 2014, 135, 76–80. [CrossRef] [PubMed]
26. Martinez-Sanchez, J.M.; Sureda, X.; Fu, M.; Pérez-Ortuño, R.; Ballbè, M.; López, M.J.; Saltó, E.; Pascual, J.A.
Fernández E. Secondhand smoke exposure at home: Assessment by biomarkers and airborne markers.
Environ. Res. 2014, 133, 111–116. [CrossRef] [PubMed]
27. Levine, H.; Berman, T.; Goldsmith, R.; Göen, T.; Spungen, J.; Novack, L.; Amitai, Y.; Shohat, T.; Grotto, I.
Exposure to tobacco smoke based on urinary cotinine levels among Israeli smoking and nonsmoking adults:
A cross-sectional analysis of the first Israeli human biomonitoring study. BMC Public Health 2013, 13, 1241.
[CrossRef] [PubMed]
28. Kim, H.; Lim, Y.; Lee, S.; Kim, C.; Hong, C.; Shin, D. Relationship between environmental tobacco smoke and
urinary cotinine levels in passive smokers at their residence. J. Expo. Anal. Environ. Epidemiol. 2004, 14 (Suppl. 1),
S65–S70. [CrossRef] [PubMed]
29. Simoni, M.; Baldacci, S.; Puntoni, R.; Pistelli, F.; Farchi, S.; Lo Presti, E.; Pistelli, R.; Corbo, G.; Agabiti, N.;
Basso, S.; et al. Plasma, salivary and urinary cotinine in non-smoker italian women exposed and unexposed
to environmental tobacco smoking (SEASD study). Clin. Chem. Lab. Med. 2006, 44, 632–638. [CrossRef]
[PubMed]
30. SIVR. Società italiana valori di riferimento. Fourth list of reference values for elements, organic compounds
and their metabolites (Quarta lista dei valori di riferimento per elementi, composti organici e loro metaboliti).
Available online: www.valoridiriferimento.it (accessed on 20 December 2017).
31. Ranzi, A.; Fustinoni, S.; Erspamer, L.; Campo, L.; Gatti, M.G.; Bechtold, P.; Bonassi, S.; Trenti, T.; Goldoni, C.A.;
Bertazzi, P.A.; et al. Biomonitoring of the general population living near a modern solid waste incinerator:
A pilot study in Modena, Italy. Environ. Int. 2013, 61, 88–97. [CrossRef] [PubMed]
32. De Craemer, S.; Croes, K.; van Larebeke, N.; Sioen, I.; Schoeters, G.; Loots, I.; Nawrot, T.; Nelen, V.; Campo, L.;
Fustinoni, S.; et al. Investigating unmetabolized polycyclic aromatic hydrocarbons in adolescents' urine as
biomarkers of environmental exposure. Chemosphere 2016, 155, 48–56. [CrossRef] [PubMed]
33. Campo, L.; Fustinoni, S.; Consonni, D.; Pavanello, S.; Kapka, L.; Siwinska, E.; Mielzynˇska, D.; Bertazzi, P. Urinary
carcinogenic 4-6 ring polycyclic aromatic hydrocarbons in coke oven workers and in subjects belonging to the
general population: Role of occupational and environmental exposure. Int. J. Hyg. Environ. Health 2014, 217,
231–238. [CrossRef] [PubMed]
34. Merlo, F.; Andreassen, A.; Weston, A.; Pan, C.F.; Haugen, A.; Valerio, F.; Reggiardo, G.; Fontana, V.; Garte, S.;
Puntoni, R.; et al. Urinary excretion of 1-hydroxypyrene as a marker for exposure to urban air levels of
polyciclic aromatic hydrocarbons. Cancer Epidemiol. Biomarkers Prev. 1998, 7, 147–155. [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 1156 15 of 15
35. Bartolomé, M.; Ramos, J.J.; Cutanda, F.; Huetos, O.; Esteban, M.; Ruiz-Moraga, M.; Calvo, E.; Pérez-Gómez, B.;
González, O.; Castaño, A.; et al. Urinary polycyclic aromatic hydrocarbon metabolites levels in a representative
sample of the Spanish adult population: The BIOAMBIENT.ES project. Chemosphere 2015, 135, 436–446.
[CrossRef] [PubMed]
36. Chetiyanukornkul, T.; Toriba, A.; Kizu, R.; Hayakawa, K. Urinary 2-hydroxyfluorene and 1-hydroxypyrene
levels in nonsmokers in japan and Thailand. Polycycl. Aromat. Compd. 2004, 24, 467–474. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
